AstraZeneca’s executive team under CEO Pascal Soriot confidently batted down Pfizer’s $120 billion takeover bid by putting an extraordinary valuation on its pipeline, often far exceeding the most optimistic forecasts by industry analysts. And now there appears to be a growing movement among a group of disenchanted investors at the U.K. company to hold management’s incentive packages hostage to the sky-high expectations they’ve created.

…read more

Source: Rebel AstraZeneca investors push plan to tie exec pay to rosy R&D projections


0 No comments